Core Viewpoint - CAR-T cell therapy has achieved significant success in treating hematological cancers, but faces numerous challenges in solid tumors, including T cell exhaustion, off-target toxicity, and the immunosuppressive tumor microenvironment [2] Group 1: Challenges in CAR-T Cell Therapy - T cell exhaustion leads to decreased anti-tumor activity, while "on target off tumor" toxicity can harm normal cells [2] - The solid tumor microenvironment is characterized by hypoxia and immunosuppressive cells and molecules, which inhibit CAR-T cell immune responses and hinder their localization and infiltration [2] Group 2: Advances in CAR-T Cell Therapy - Recent research highlights various strategies to enhance CAR-T cell therapy for solid tumors, including immune checkpoint inhibition, targeted antigen selection, gene editing, dual-targeting, and combination therapies [2] - Blocking PD-1 signaling can enhance CAR-T cell persistence and reduce T cell exhaustion, with methods such as PD-1 antibodies and shRNA showing promise [4] - Combining CAR-T cell therapy with local CD47 blockade can reverse immune suppression in the tumor microenvironment [4] Group 3: Cytokine Engineering - Cytokine engineering of CAR-T cells is a promising strategy to overcome limitations in solid tumors, with membrane-bound IL-12 and IL-15 enhancing anti-tumor efficacy and T cell proliferation [8] - IL-18 can improve T cell and NK cell activity, with engineered CAR-T cells showing significant anti-tumor effects in mouse models [8] Group 4: Targeting Tumor Microenvironment - Targeting the TGF-β pathway can alleviate T cell exhaustion and excessive cytokine release, making it a potential target for optimizing CAR-T cell therapy [9] - The extracellular matrix (ECM) poses a barrier to CAR-T cell infiltration, with new technologies enabling CAR-T cells to degrade ECM and improve their infiltration capabilities [11] Group 5: Gene Editing and Multi-Design Approaches - Gene editing strategies, such as knocking down multiple inhibitory factors, have been shown to enhance CAR-T cell activity against cholangiocarcinoma [13] - The development of dual-target CAR-T cells targeting EGFR and IL-13R α 2 has demonstrated improved survival rates in glioma models [9] Group 6: Industry Support - Companies like Yiqiao Shenzhou provide high-purity and high-activity target proteins to support CAR-T cell development, utilizing advanced membrane protein technology platforms [14]

Core Viewpoint - The report outlines the ongoing supervision and compliance of Suzhou Nearshore Protein Technology Co., Ltd. following its IPO on the Sci-Tech Innovation Board, highlighting the company's financial performance, governance, and compliance with regulatory requirements [1][2][3]. Continuous Supervision Work - The sponsoring institution has established a robust supervision system and executed a work plan to ensure compliance with relevant regulations [1]. - Regular communication, site visits, and due diligence have been conducted to monitor the company's operations [1][2]. - The company has faced issues related to unauthorized share reductions by shareholders, leading to public apologies and share repurchases [2][3]. Financial Performance - The company reported a significant decline in net profit, with a loss of 54.42 million yuan, a decrease of 523.68% year-on-year, attributed to macroeconomic conditions and increased operational costs [11][12]. - Revenue for the year was 127.56 million yuan, down 16.73% from the previous year, indicating challenges in market demand and operational efficiency [11][12]. Core Competitiveness - The company has developed 23 core technologies and established seven comprehensive technology platforms, which are crucial for maintaining its competitive edge in the recombinant protein industry [12][13]. - The company emphasizes innovation and has a strong focus on R&D, with R&D expenses accounting for 39.14% of revenue, reflecting a commitment to technological advancement [20]. Industry Risks - The recombinant protein industry is characterized by intense competition and rapid technological changes, which may pose risks to the company's market position if it fails to keep pace with innovations [8][9]. - Regulatory changes and market dynamics, particularly in the mRNA vaccine sector, present uncertainties that could impact the company's sales and operational stability [10]. Governance and Compliance - The company has implemented a comprehensive internal control system and governance structure to ensure compliance with legal and regulatory standards [4][5]. - Continuous monitoring of the company's adherence to commitments and regulatory requirements is a priority for the sponsoring institution [5][6]. Talent and R&D Development - The company has a strong technical team and management, which is essential for sustaining its innovation and competitive advantage [19]. - Ongoing investments in R&D are aimed at enhancing product offerings and expanding market reach, with a focus on mRNA and diagnostic products [13][14].